



**Doncaster Place and Bassetlaw Place  
Medicines Optimisation Bulletin**

**February 2026**

**Useful hyperlinks for Medicines Optimisation To open Press control and click the link below  
[South Yorkshire Central ICB Medicines Optimisation Website.](#) [MPD](#)**

**Contact us on : South Yorkshire Medicines Optimisation Team SY MOT : [syicb-sheffield.syicb.medsopt1@nhs.net](mailto:syicb-sheffield.syicb.medsopt1@nhs.net)**

**Please Note that documents and information is correct at date of publication but please refer to the MO website for most up to date information. Do not refer to back issues of the bulletin as information may change and documents can be updated. Always ensure you are referring to the latest version.**

**Hot off the Press**

**New / Updated Guidance on MO website**

- Tirzepatide weight management patient information leaflet (short version) - [Click here](#)
- SY Asthma Guidance - [Click Here](#) and COPD Guidance - [Click Here](#)
- Migraine documents update - amber G :Atogepant and Rimegepant for prevention - [Click Here](#)
- 3rd party ordering position statement – [Click Here](#)
- Inflammatory Arthritis, Connective Tissue Disease and systemic Vasculitis SCP and Proforma with changes to reflect the latest BSR guidelines V8.2 - [Click Here](#)
- Denosumab SCP – [Click Here](#)

**MHRA SAFETY INFORMATION February 2026**

**Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs for full information [click Here](#)**

**Tirzepatide is not licensed for type1 diabetes mellitus Practices have raised queries about the prescribing of Tirzepatide (Mounjaro) for patients with type 1 diabetes. Endocrinology specialists at DBTHFT have advised that this represents off-licence use and that for patients with type 1 diabetes Tirzepatide would be initiated and continued only on an individual patient basis, under strict ongoing review by the endocrinology team. Prescribing for off-licence use would remain with secondary care.**

**Formulary updates February 2025**

The following items will be added/amended on the [MPD](#)

Formulary Section	Item	Indication	PMOC Action
4.7.4	Atogepant	Prevention of episodic and chronic migraine	Amended on MPD from <b>Red to Amber G</b> (prevention)
4.7.4	Rimegepant	Prevention of episodic migraine	Amended on MPD from <b>Red to Amber G</b> (prevention)
3.2	Trixeo (ICS/LABA/LAMA triple therapy)	COPD	Amended from 2 <sup>nd</sup> line to 1 <sup>st</sup> line
3.2	Trimbow (ICS/LABA/LAMA triple therapy)	COPD	Amended from 1 <sup>st</sup> line to 3 <sup>rd</sup> line
3.1.4	Spiolto Respimat	COPD	Added to MPD as 2 <sup>nd</sup> line
4.5.2	Tirzepatide	Weight management	New status – <b>Grey</b> (any patients that fall out of NICE guidance TA1026)
7.1.1	Progesterone 400mg soft vaginal capsules	Indicated for the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages.	Added to MPD as Amber G
4.9.3	Primidone	Essential Tremor	Added to MPD as Green
17.2	Intravaginal device, ring and shelf pessaries	Non-surgical management of pelvic floor dysfunction	Added to MPD as Green

**For the latest Out of Stock information Refer to your regular emails from medicines management Admin emails.**